Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$355.93 USD

355.93
153,736

+5.86 (1.67%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $355.74 -0.19 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars

Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.

    United Therapeutics (UTHR) Up 0.4% Since Last Earnings Report: Can It Continue?

    United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip

      United Therapeutics (UTHR) reports unimpressive second-quarter earnings. Sales rise sequentially. Shares sink 5%.

        United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

        United Therapeutics (UTHR) delivered earnings and revenue surprises of 29.76% and 27.27%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

          Tirthankar Chakraborty headshot

          New Strong Buy Stocks for July 9th

          Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

            United Therapeutics (UTHR) Up 3.9% Since Earnings Report: Can It Continue?

            United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              United Therapeutics (UTHR) Q1 Earnings Rise, Sales Drop Q/Q

              United Therapeutics' (UTHR) earnings per share rise in the first quarter. Sales drop sequentially due to unfavorable timing of distributor orders. Shares sink almost 7%.

                Why Is United Therapeutics (UTHR) Down 10.7% Since Its Last Earnings Report?

                United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Should Value Investors Pick United Therapeutics (UTHR) Stock?

                  United Therapeutics (UTHR) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

                    United Therapeutics (UTHR) Q4 Earnings Decline on High Costs

                    United Therapeutics' (UTHR) earnings per share decline in Q4 due to higher operating costs. Shares sink almost 10%.

                      United Therapeutics (UTHR) Collaborates With Corsair Pharma

                      United Therapeutics (UTHR) entered into an exclusive license agreement with Corsair Pharma.

                        United Therapeutics PAH Drug's Exclusivity Period Extended

                        United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.

                          United Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat

                          United Therapeutics' (UTHR) earnings grow year over year in the third quarter of 2017. Revenues too surpass estimates in the reported quarter.

                            Is United Therapeutics a Great Stock for Value Investors?

                            Let's see if United Therapeutics Corporation (UTHR) stock is a good choice for value-oriented investors right now from multiple angles.

                              J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use

                              Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved a label expansion for its oral pulmonary arterial hypertension (PAH) medicine, Tracleer.

                                United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top

                                United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.

                                  Madeleine Johnson headshot

                                  Here's Why Arena Pharmaceuticals (ARNA) Stock is Skyrocketing Today

                                  On Tuesday, shares of biopharmaceutical company Arena Pharmaceuticals (ARNA) are skyrocketing, up about 41% to $26.10 per share in afternoon trading after it reported positive mid-stage trial results for one of its drugs.

                                    Arena's Ralinepag Positive in Phase II PAH Study, Shares Up

                                    Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.

                                      Cardiome's Partner SteadyMed Submits NDA for PAH Injection

                                      Cardiome Pharma Corp. (CRME) announced that its partner SteadyMed Ltd. (STDY) has submitted a new drug application (NDA) to the FDA for its lead candidate, Trevyent (treprostinil injection), for treatment of pulmonary arterial hypertension (PAH).

                                        Arena Ends Study on Extended Release Formulation of PAH Drug

                                        Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.

                                          United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

                                          United Therapeutics Corporation (UTHR) reported adjusted earnings of $3.89 per share (including stock-based compensation benefit) for the first quarter of 2017

                                            Company News for April 04, 2017

                                            Companies in the News are: DRYS,VW,CAT,UTHR

                                              United Therapeutics Tanks, Remodulin Pump Launch Delayed

                                              United Therapeutics Corporation (UTHR) shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for delivering Remodulin

                                                Why Is United Therapeutics (UTHR) Down 5.6% Since the Last Earnings Report?

                                                United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Is United Therapeutics a Great Stock for Value Investors?

                                                  Let's see if United Therapeutics Corporation (UTHR) stock is a good choice for value-oriented investors right now from multiple angles.